FIELD: immunology.
SUBSTANCE: invention refers to clinical immunology and haemostasiology. Disclosed is a method for determining a thrombin pathway of complement system activation (TPCSA) by human group A erythrocysis lysis, involving using citrated human blood plasma as a source of circulating thrombin, its natural substrate - component C5 and proteins of membrane-attack complex C6, C7, C8 and C9, proteolysis of component C5 of complement thrombin leads to formation of membrane-attack complex and lysis of added erythrocyte 1 % suspension, the TPCSA activity in the sample is determined by turbidimetry after 10-minute incubation at 37 °C according to the calibration curve, where 100 % lysis is complete lysis of human erythrocytes with water addition, and control of erythrocytes on spontaneous lysis - 0 % lysis, in lysis to 30 % human erythrocytes is considered normal activity of thrombin path complement system, from 30 to 60 % - increased activity and more than 60 % of lysis - high activity of human complement's thrombin pathway.
EFFECT: invention provides a novel approach for determining activity of a thrombin pathway of complement system activation, simplifies testing and eliminates multiple contact of the operator with the biomaterial.
1 cl, 3 dwg, 7 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
DETERMINING HUMAN ERYTHROCYTE SENSITIVITY TO LYSIS WITH COMPLEMENT SYSTEM ACTIVATION ON THROMBIN PATHWAY | 2019 |
|
RU2696981C1 |
DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
SCREENING TEST FOR DETERMINATION OF THE FUNCTIONAL ACTIVITY OF THE RAT COMPLEMENT SYSTEM | 2022 |
|
RU2786208C1 |
METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 | 2023 |
|
RU2814496C1 |
DETERMINING THE ACTIVITY OF THE CLASSICAL PATHWAY OF THE COMPLEMENT SYSTEM IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2707568C1 |
METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
METHOD FOR DETERMINING ACTIVITY OF MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASES IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2739113C1 |
DIRECT THROMBIN INHIBITOR, POSSESSING ANTIPROLIFERATIVE ACTION | 2007 |
|
RU2369615C2 |
APTAMER OLIGONUCLEOTIDE - DIRECT THROMBIN INHIBITOR | 2008 |
|
RU2401306C2 |
Authors
Dates
2020-03-27—Published
2019-06-13—Filed